belviq.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Belviq |
| Description | Belviq --> Prescribing Information | Please click here to readthe FDA Drug SafetyCommunication for Belviq Eisai Inc. announced that it will voluntari |
| Keywords | N/A |
Server Information
| WebSite | |
| Host IP | 208.74.145.245 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
belviq.com Valuation
|
US$11,984,541
Last updated: 2023-05-11 16:20:55
belviq.com has Semrush global rank of 883,163. belviq.com has an estimated worth of US$ 11,984,541, based on its estimated Ads revenue. belviq.com receives approximately 1,382,832 unique visitors each day. Its web server is located in United States, with IP address 208.74.145.245. According to SiteAdvisor, belviq.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$11,984,541 |
| Daily Ads Revenue | US$11,063 |
| Monthly Ads Revenue | US$331,880 |
| Yearly Ads Revenue | US$3,982,556 |
| Daily Unique Visitors | 92,189 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| belviq.com. | A | 10800 | IP: 208.74.145.245 |
| belviq.com. | NS | 10800 | NS Record: ns1.acompany.global. |
| belviq.com. | NS | 10800 | NS Record: ns2.acompany.global. |
| belviq.com. | NS | 10800 | NS Record: ns3.acompany.global. |
| belviq.com. | TXT | 10800 | TXT Record: b7dc06ee67ec4731b0fb46ec74148c93 |
| belviq.com. | TXT | 10800 | TXT Record: v=spf1 -all |
HtmlToTextCheckTime:2023-05-11 16:20:55
| Belviq --> Prescribing Information | Please click here to readthe FDA Drug SafetyCommunication for Belviq Eisai Inc. announced that it will voluntarily withdraw from the market and discontinue sales of BELVIQ® (lorcaserin HCl) CIV and BELVIQ XR (lorcaserin HCl) CIV in the U.S. This action is being taken after a request from the U.S. Food and Drug Administration (FDA), based on the Agency’s recently completed analysis of data from the CAMELLIA-TIMI 61 trial. At the time of marketing approval from BELVIQ, the FDA required Eisai to perform a long-term trial evaluating the cardiovascular effects associated with the use of the drug. The CAMELLIA-TIMI 61 trial for lorcaserin was a randomized, double-blind, placebo-controlled clinical trial to study approximately 12,000 men and women over five years with established cardiovascular disease or at high risk for cardiovascular disease. This study was conducted at over 400 sites in eight countries including the U.S. and is the largest |
HTTP Headers
HTTP/1.1 200 OK Content-Length: 5293 Content-Type: text/html Last-Modified: Fri, 14 Feb 2020 19:38:27 GMT Accept-Ranges: bytes ETag: "af324546ee3d51:0" Server: Microsoft-IIS/10.0 X-Powered-By: ASP.NET Origin: Prod_CD1 Date: Fri, 05 Nov 2021 09:16:55 GMT |
belviq.com Whois Information
Domain Name: BELVIQ.COM Registry Domain ID: 1660599813_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.rrpproxy.net Registrar URL: http://www.key-systems.net Updated Date: 2021-05-08T03:01:14Z Creation Date: 2011-06-08T20:47:59Z Registry Expiry Date: 2022-06-08T20:47:59Z Registrar: Key-Systems GmbH Registrar IANA ID: 269 Registrar Abuse Contact Email: abuse@key-systems.net Registrar Abuse Contact Phone: +49.68949396850 Domain Status: ok https://icann.org/epp#ok Name Server: NS1.FSIWEBS.NET Name Server: NS2.FSIWEBS.NET DNSSEC: unsigned >>> Last update of whois database: 2021-11-05T07:15:34Z <<< |